When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
EDSA - Edesa Bio enrolls first patient in mid-stage dermatitis study
Edesa Biotech Inc.
A first patient has been enrolled in Edesa Biotech's (NASDAQ:EDSA) Phase 2b clinical trial evaluating EB01, as a monotherapy for patients with moderate to severe chronic allergic contact dermatitis (ACD).
More news on: Edesa Biotech, Inc., Healthcare stocks news,